Orion Pharma account plan
Pharmaceuticals oncology pain treatment
At a glance
Orion is a Finnish pharmaceutical group in human and veterinary medicines and APIs: EUR 1,889.5 million FY2025 net sales, about 4,000 people.
Orion Corporation, headquartered in Espoo and listed on Nasdaq Helsinki, develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients, with R&D focused on oncology and pain. It sells in over one hundred countries through its own network in Europe and six Asia-Pacific countries and through partners elsewhere, and runs eight production sites (six in Finland, one in France, one in Belgium). FY2025 net sales rose 22.5% to EUR 1,889.5 million and operating profit 51.6% to EUR 631.6 million, driven by royalties on the prostate cancer drug Nubeqa® partnered with Bayer. Personnel was 4,029 at year-end 2025. A shares carry 20 votes and B shares one vote.
Business units
Innovative Medicines
EUR 812.7 million, 43% of FY2025 net salesPatent-protected medicines in oncology and pain, led by Nubeqa® (darolutamide), sold by Bayer with Orion earning royalties and supplying the product; Nubeqa® was EUR 609.8 million in 2025 (+65.6%). It became Orion's biggest division in 2026, with 9M sales of EUR 675.6 million (+62.5%). Led by Berkeley Vincent (EVP Innovative Medicines from April 2026), with Outi Vaarala as EVP R&D.
Generics and Consumer Health
EUR 552.8 million, 29% of FY2025 net salesGeneric prescription medicines and consumer health products, strongest in Finland, the Baltics and Scandinavia, plus value-added generics for European hospitals. Sales grew 4.6% in 2025 but fell 1.0% over 9M 2026. From 1 January 2027 it moves under Juhani Kankaanpää's Global Operations as Satu Ahomäki leaves.
Branded Products
EUR 314.6 million, 17% of FY2025 net salesIn-house developed brands in Respiratory (the Easyhaler® portfolio), CNS and Women's Health (Divina®), positioned as the platform for growth in Europe and Asia. Grew 9.4% in 2025 and 10.1% over 9M 2026. From 2027 it is led by Henri Salokangas and adds a Europe-wide hospital business.
Animal Health
EUR 140.9 million, 7% of FY2025 net salesProprietary and generic products for companion animals and livestock, including sedatives such as Dexdomitor®. Grew 9.9% in 2025 but slipped 1.8% over 9M 2026 on delivery timing and delayed shipments to the Middle East and Africa; the FDA approved Tessie® for dogs in 2026. Led by Niclas Lindstedt.
Fermion
EUR 68.7 million external sales, 4% of FY2025 net salesActive pharmaceutical ingredients for Orion and other drug makers, plus contract development and manufacturing; it makes key APIs for all divisions. External sales fell 5.0% in 2025 on capacity constraints, then rose 21.5% over 9M 2026. Part of Global Operations under Juhani Kankaanpää; Kim Nylund is Senior Vice President of Fermion.
Strategic priorities
- Grow Nubeqa® with Bayer
- Nubeqa® royalties reached the highest tier in Q2 2026 and now track Bayer's market sales; Orion estimates its Nubeqa net sales could exceed EUR 1 billion by the end of the decade, relying on the 2033 basic patent.
- Build the innovative pipeline
- Advance ODM-212 (TEAD inhibitor), with Phase 2 readout expected in late 2027 and Phase 3 run by Orion itself, and the first biologic ODM-216, which entered Phase 1 in September 2026.
- Geographic expansion
- Strengthen Europe, expand in Asia Pacific including Japan, and establish US R&D and commercial operations, starting with a Boston team of "tens of people".
- Sharper commercial organisation
- From 1 January 2027 a new International Commercial Operations under Hao Pan covers all ex-US commercial activity, while generics move under Global Operations.
- 2024-2028 financial targets
- Net sales CAGR of at least 8%, operating profit growing faster than sales, equity ratio of at least 50% and ROE of 25% or higher.
Latest results
In January-September 2026 net sales rose 24.1% to EUR 1,481.5 million and operating profit 65.2% to EUR 501.2 million. Q3 alone brought net sales of EUR 542.2 million (+28.1%) and operating profit of EUR 209.9 million (38.7% margin), with Nubeqa® at EUR 279.9 million as the highest royalty tier applied all quarter. Branded Products grew 10.8% in Q3 while Generics and Consumer Health fell 3.4%. On 20 October 2026 Orion raised its 2026 outlook to net sales of EUR 2,070-2,140 million and operating profit of EUR 730-790 million, excluding material milestones. It had a net cash position at 30 September 2026 (gearing -1.3%).
Investments and deals
- R&D spending
- R&D expenses were EUR 210.4 million in 2025 (11.1% of net sales) and EUR 168.2 million in 9M 2026 (+20.3%), with all projects running at once.
- Darolutamide supply capacity
- Part of the darolutamide API is moving to a European contract manufacturer and a US-based contract manufacturer to manage supplier risk; tablets remain made in Orion's own plant.
- Cambridge R&D centre
- A new R&D centre in Cambridge, UK, focused on biologics and large molecules, part of 2025 capex of EUR 112.9 million.
- Licensing deals
- Biosimilar licences from Shilpa (IV nivolumab) and Qilu (IV pembrolizumab) for Europe, with launches expected in the early 2030s, and the APORON® apomorphine spray licence from Criceto.
- MSD opevesostat licence
- MSD holds a global licence for opevesostat, with Orion eligible for up to USD 30 million development, USD 625 million regulatory and USD 975 million sales milestones plus royalties.
Challenges and risks
- Dependence on Nubeqa® and Bayer
- Bayer represented about EUR 808.9 million of 2025 revenue, and the predictability of Nubeqa® royalties is a stated risk.
- US pharmaceutical tariffs
- Tariffs on Nubeqa were expected from October 2026, minor for Q4, with a bigger impact expected in 2027.
- Supply-chain and production risk
- Risks include disruption of own production and supplier dependence, illustrated by the July 2026 water damage at Fermion's Hanko plant, which will weigh on Fermion's Q4 external sales.
- Generics price competition
- Tougher price competition and regulatory change weigh on generics, which fell 3.4% in Q3 2026 on many small declines.
- R&D timing and failures
- Partner Tenax's LEVEL Phase 3 trial of oral levosimendan missed its endpoints in 2026, and ODM-105 was terminated after failing Phase 2.
What leadership says
“We have not changed our strategy. On the contrary, our strategy has become a necessity.”
“we have a potentially best-in-class TEAD inhibitor in our hands”
“almost half of Orion's revenue comes from innovative medicines after the first nine months”
“when you build resilience, there is, of course, some price to that”
Where a supplier can help
- API capacity and contract manufacturing
- Tied to the darolutamide supply investment and supply-chain risk: CDMOs, quality and supplier-qualification services help Orion add resilient capacity.
- US build-up support
- Tied to the geographic expansion priority: recruiting, regulatory, medical affairs and market access services for the Boston team preparing ODM-212 Phase 3.
- Clinical development capacity
- Tied to the pipeline priority and rising R&D spend: CROs, trial sites and biologics development partners for ODM-212, ODM-216 and the Cambridge centre.
- Commercial operations reorganisation
- Tied to the new International Commercial Operations from 2027: CRM, sales analytics and commercial excellence tools for a unified ex-US organisation.
- Generics cost and service efficiency
- Tied to generics price competition: supply planning, procurement and logistics tools for a business management calls "really about supply, price, and service level".
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Orion Pharma?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Orion Corporation Financial Statement Documents 2025
- Orion Corporation is a Finnish pharmaceutical group (HQ Espoo, A and B shares on Nasdaq Helsinki) that develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients; core R&D therapy areas are oncology and pain.
- FY2025 net sales rose 22.5% to EUR 1,889.5 million (2024: 1,542.4), of which milestones EUR 183.4 million; operating profit rose 51.6% to EUR 631.6 million (33.4% margin); profit for the period EUR 500.3 million; basic EPS EUR 3.56; proposed dividend EUR 1.80 per share.
- Nubeqa® (darolutamide, prostate cancer, partnered with Bayer) is the engine: EUR 609.8 million in 2025 (+65.6%), of which royalties EUR 432.5 million, plus a EUR 180 million milestone; Orion estimates its Nubeqa net sales could exceed EUR 1 billion by the end of the decade.
- Five business divisions: Innovative Medicines EUR 812.7 million (43% of net sales), Generics and Consumer Health EUR 552.8 million (29%), Branded Products EUR 314.6 million (17%), Animal Health EUR 140.9 million (7%), Fermion (APIs) EUR 68.7 million (4%).
- Geography: Other Europe EUR 530.2 million, North America EUR 481.1 million, Finland EUR 365.6 million, Rest of the World EUR 323.0 million, Scandinavia EUR 189.6 million; one major customer (Bayer) represented about EUR 808.9 million of revenue.
- Strategy: build a customer-driven portfolio, expand geographically (strengthen Europe, expand in Asia Pacific including Japan, establish US R&D and commercial operations) and develop growth enablers; 2024-2028 targets are net sales CAGR of at least 8%, operating profit growing faster than sales, equity ratio of at least 50%, ROE of 25% or higher.
- R&D spend EUR 210.4 million (11.1% of sales) and capex EUR 112.9 million; new R&D centre in Cambridge, UK; MSD licence on opevesostat worth up to USD 30 million development, USD 625 million regulatory and USD 975 million sales milestones; ODM-212 (TEAD inhibitor) entered Phase 2.
- 2026 outlook (14 January 2026): net sales EUR 1,900-2,100 million and operating profit EUR 550-750 million, with no material milestones assumed; key risks are US pharma tariffs, Nubeqa royalty predictability, supply-chain disruption, price competition and R&D timing.
- About 4,000 people (4,029 at year end); 8 production sites (six in Finland, one in France, one in Belgium); CEO Liisa Hurme, CFO René Lindell, Chair Veli-Matti Mattila.
- Orion Group Half-Year Financial Report January-June 2026
- H1 2026 net sales EUR 939.3 million (+21.8% vs 771.0) and operating profit EUR 291.3 million (+59.6%); Q2 alone net sales EUR 521.6 million (+25.2%) and operating profit EUR 176.6 million (+68.8%, 33.9% margin).
- Nubeqa® drove growth: H1 EUR 381.8 million (+64.9%), of which royalties EUR 267.4 million (+79.0%); the highest tier of the annual Nubeqa® royalty scale was reached in Q2.
- Innovative Medicines H1 EUR 392.0 million (+60.3%); Branded Products EUR 172.9 million (+9.9%, Divina® +47.6%); Generics and Consumer Health EUR 267.4 million (+0.3%); Animal Health EUR 70.2 million (-2.4%); Fermion EUR 36.8 million (+17.1%).
- Outlook narrowed upward on 17 July 2026: net sales EUR 2,000-2,100 million (was 1,950-2,100) and operating profit EUR 650-750 million (was 600-750).
- Pipeline: ODM-212 (TEAD inhibitor) started TEADCO Phase 1b/2, presented Phase 1 TEADES data at ASCO and got orphan designations in the US and EU; FDA approved Animal Health's Tessie® for dogs, partner sales expected mid-2027.
- Cash flow from operations EUR 311.8 million (+98.7%) after receipt of the EUR 180 million Nubeqa® milestone; loans of EUR 161.0 million repaid; gearing 0.2%, equity ratio 67.9%.
- Berkeley Vincent appointed EVP Innovative Medicines (from April 2026); Shilpa licence for an IV nivolumab biosimilar in Europe (launch expected early 2030s); water damage at Fermion's Hanko plant in July, not expected to be material.
- Orion Group Interim Report January-September 2026
- Q3 2026 net sales EUR 542.2 million (+28.1%) and operating profit EUR 209.9 million (+73.5%, 38.7% margin); January-September net sales EUR 1,481.5 million (+24.1%) and operating profit EUR 501.2 million (+65.2%).
- Nubeqa® Q3 EUR 279.9 million (+69.0%), royalties EUR 222.3 million (+88.1%) with the highest royalty tier applying all quarter; 9M Nubeqa® EUR 661.7 million.
- Outlook upgraded on 20 October 2026: net sales EUR 2,070-2,140 million and operating profit EUR 730-790 million (previously 2,000-2,100 and 650-750).
- Branded Products Q3 +10.8% (Women's Health +45.5%); Generics and Consumer Health -3.4%; Animal Health -0.3%; Fermion +31.6% on contract development and manufacturing.
- Darolutamide API capacity expanded through a European contract manufacturer and a US-based contract manufacturer.
- Pipeline: first biologic, bispecific antibody ODM-216, entered Phase 1 (BICIDES); DASL-HiCaP interim Phase 3 data showed a 58% reduction in risk of metastasis or death; Tenax's LEVEL Phase 3 missed its endpoints.
- Qilu licence (October) for an IV pembrolizumab biosimilar in Europe, launch expected early 2030s.
- Executive Team changes from 1 January 2027: new International Commercial Operations led by Hao Pan as EVP and Chief Commercial Officer; Henri Salokangas EVP Branded Products; Satu Ahomäki leaving; Juhani Kankaanpää adds Generics and Consumer Health to Global Operations.
- Net cash position (gearing -1.3%); 500,000 B shares bought back for about EUR 40.5 million for incentive plans.
- Orion Q3 2026 conference call and webcast (transcript)
- CEO Liisa Hurme and CFO René Lindell presented Q3 2026 (net sales EUR 542 million, +28%; operating profit EUR 210 million) and the raised outlook of EUR 2,070-2,140 million sales and EUR 730-790 million operating profit.
- Hurme: almost half of Orion's revenue after nine months comes from Innovative Medicines (Nubeqa® royalties and product sales); the maximum royalty rate was reached in Q2, so Q4 royalties now track Bayer's in-market sales.
- The strategy launched in 2023 has "become a necessity": Orion is moving to a next stage that sharpens focus on strategic assets, with a new international commercial organisation under Hao Pan and US operations under Berkeley Vincent.
- Branded Products gains a Europe-wide hospital business (Simdax, Dexdor, biosimilars, recombinant albumin); generics, "really about supply, price, and service level", moves under Global Operations.
- Darolutamide API is being dual-sourced (Hong Kong, Germany, and a US site) to manage supplier risk; the gross-margin impact "will be marginal" (Lindell). Tablets stay in Orion's own plant.
- Pipeline: first biologic ODM-216 in Phase 1, possibly another Phase 1 programme this year; Orion plans to run ODM-212 Phase 3 itself; it would opt in to DASL-HiCaP if Bayer files.
- Bayer expects Nubeqa to be its biggest product (around EUR 5 billion, Hurme); Orion relies on the 2033 basic patent. AI has helped halve discovery and research time.
- US tariffs on Nubeqa expected from October, minor for Q4; animal health shipments to the Middle East and Africa delayed by geopolitics.
- Orion Half-Year 2026 conference call and webcast (transcript)
- CEO Liisa Hurme and CFO René Lindell presented H1 2026 on 17 July 2026: Q2 net sales EUR 522 million (+25%) and operating profit EUR 177 million (+69%, 34% margin); outlook raised to EUR 2-2.1 billion sales and EUR 650-750 million operating profit.
- Hurme: Innovative Medicines is now Orion's biggest division, ahead of Generics and Branded Products; Nubeqa royalty income is "very back-end loaded" within a year and the top royalty tier was reached in Q2.
- ODM-212 (TEAD inhibitor) is pitched as "potentially best-in-class": Phase 2 in mesothelioma and EHE reads out in late 2027, the Phase 1b/2 combination study in 2029; Orion plans to run Phase 3 itself with no partner.
- Divina® grows around 40% a year, helped partly by competitor HRT stock-outs in the Nordics; Fermion's Hanko water damage is a matter of "rather weeks than months".
- US build-up: a Boston team in clinical, regulatory and R&D plus a new US commercial head; "tens of people, not hundreds", with a real cost step only near launch.
- Lindell: US tariffs on European innovative pharma assumed from October, small in 2026 and bigger in 2027; the gross margin rise comes mainly from Nubeqa royalties.
- Excluding Simdax and Dexdor, generics grew 2%; FDA approved Tessie® for dogs, partner launch mid-2027.
Questions about Orion Pharma
What does Orion Corporation do?
Orion is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients, with R&D in oncology and pain.
What is Orion's revenue?
FY2025 net sales were EUR 1,889.5 million (+22.5%) and operating profit EUR 631.6 million. The 2026 outlook is net sales of EUR 2,070-2,140 million and operating profit of EUR 730-790 million.
How many employees does Orion have?
Orion had 4,029 people at the end of 2025; the average headcount in January-September 2026 was 4,174.
Who leads Orion?
Liisa Hurme is President and CEO, René Lindell is CFO, and Veli-Matti Mattila chairs the Board.
What is Orion's strategy?
Build a customer-driven portfolio, expand geographically in Europe, Asia Pacific and the US, and develop growth enablers, targeting net sales CAGR of at least 8% over 2024-2028.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)